Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BI 836858

Monoclonal antibody · Immune activation, directed at CD33 · developed by Boehringer Ingelheim

Phase 2/3 Most advanced trial
1 Registered trials

What is BI 836858?

BI 836858 is a fully human IgG1 anti-CD33 monoclonal antibody that induces antibody-dependent cellular cytotoxicity against CD33-expressing myeloid leukemia cells. It is studied in previously untreated, relapsed, and refractory acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
CD33
Mechanism
Immune activation, directed at CD33
Pathways
antibody-dependent cellular cytotoxicity
Therapy area
Hematology, Oncology
Developer
Boehringer Ingelheim
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
JA7I0QFJ17

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on CD33

Actinium Ac 225 Lintuzumab Phase 1 Lintuzumab Phase 1 Lintuzumab-Ac225 Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.